News
Changes to pharmaceutical policy during an economic recession
2015-07-06 The use of antipsychotic medicines across Finland and Portugal following the recent economic recession have been analysed in order to gauge the impact of contrasting… Read More »
Biosimilar bevacizumab similar to Avastin in preclinical assessments
2015-07-02 Amgen’s biosimilar bevacizumab candidate (ABP 215) to Avastin [1]. Bevacizumab is a humanized monoclonal antibody. It inhibits angiogenesis (the formation of new blood vessels) by… Read More »
Extrapolation for biosimilars
2015-06-30 Regarding extrapolation* of indications for biosimilars, the European Medicines Agency (EMA) has stated that ‘if clinical similarity can be shown in a key indication, extrapolation… Read More »
Mobilization of stem cells by biosimilar Nivestim and Neupogen
2015-06-29 Comparison of biosimilar granulocyte colony-stimulating factor (G-CSF), Nivestim and originator G-CSF, Neupogen (filgrastim), showed no statistical differences when used for the mobilization of peripheral blood… Read More »
Reference pricing and generics in Finland
2015-06-26 Reference pricing and the extension of generics substitution have produced substantial savings in antipsychotic medication costs in Finland. The daily cost of treatment with clozapine,… Read More »
Thirty years of generics in the US
2015-06-26 On 24 September 2014, the US Food and Drug Administration (FDA) celebrated 30 years of generics in the US. Thirty years ago, in September 1984,… Read More »
Generics and biosimilars contribute to European drug savings
2015-06-25 As governments around the world try to rein in healthcare expenses, generics and biosimilars can play a major role in reducing this budgetary burden [1,… Read More »
Elderly patients in US lack knowledge on biosimilars
2015-06-19 A survey conducted by patient advocacy group RetireSafe finds that seniors are largely unaware of biosimilars and that they overwhelmingly support strong patient safeguards and… Read More »
Generics in Taiwan: urban–rural disparity
2015-06-17 A study of the urban–rural disparity of prescribing generic versus brand-name drugs in Taiwan has found that the generics prescribing ratio of the most popular… Read More »
Phase III study of biosimilar adalimumab meets primary endpoint
2015-06-15 Biologicals major Amgen announced on 8 October 2014 the first late-stage data from its biosimilars programme. Primary efficacy analysis from a phase III trial of… Read More »
